Aspira Women's Health Inc. Reports Board and Officer Changes

Ticker: AWHL · Form: 8-K · Filed: 2025-01-31T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-of-directors, officer-departure

Related Tickers: AWH

TL;DR

Aspira Women's Health (AWH) board shake-up: new directors elected, some officers out.

AI Summary

Aspira Women's Health Inc. announced on January 28, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its officers.

Why It Matters

Changes in board composition and officer roles can signal shifts in company strategy, leadership, and governance, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Board and officer changes can indicate internal instability or strategic realignments, which carry inherent risks.

Key Players & Entities

FAQ

Who are the specific officers that departed from Aspira Women's Health Inc.?

The filing indicates the departure of certain officers but does not name them specifically in the provided text.

Who are the newly elected directors to the Aspira Women's Health Inc. board?

The filing states that directors were elected but does not provide their names in the provided text.

What specific changes were made to the compensatory arrangements of the officers?

The filing mentions updates to compensatory arrangements but does not detail the specifics of these changes in the provided text.

What is the effective date of these board and officer changes?

The earliest event reported is January 28, 2025, which is the date of the changes.

Does this 8-K filing disclose any financial performance metrics?

No, this 8-K filing focuses on changes in directors and officers and compensatory arrangements, not financial performance.

From the Filing

0001493152-25-004329.txt : 20250131 0001493152-25-004329.hdr.sgml : 20250131 20250131061525 ACCESSION NUMBER: 0001493152-25-004329 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250128 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250131 DATE AS OF CHANGE: 20250131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 25575771 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2025-01-28 2025-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025       Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-34810   33-0595156 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12117 Bee Caves Road Building III Suite 100     Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa

View on Read The Filing